Micro-RNA: The darkhorse of cancer

Budakoti, Mridul; Panwar, Abhay Shikhar; Molpa, D.; Singh, Rahul; Büsselberg, Dietrich; Mishra, Abhay Prakash; Coutinho, Henrique Douglas Melo; Nigam, Manisha

doi:10.1016/j.cellsig.2021.109995

Cited by 97 publications

(59 citation statements)

References 182 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They regulate the mRNA by binding their seed sequences located within their 5′ ends to the 3′-untranslated regions (3′-UTRs) of the target mRNA. This ultimately results in the mRNA’s repression through its translational inhibition and/or destabilisation [ 10 , 18 ]. Through that, miRNAs affect cellular inflammation, cell cycle regulation, stress response, cell differentiation, apoptosis, metastasis, migration, and hemopoiesis [ 10 , 17 , 19 ].…”

Section: Resultsmentioning

confidence: 99%

“…Among the various types of noncoding RNAs, microRNAs are a class of short non-coding RNAs (built of 21–23 nucleotides) that repress the expression of about 30% of the genes at the post-transcriptional level [ 10 , 18 ]. They regulate the mRNA by binding their seed sequences located within their 5′ ends to the 3′-untranslated regions (3′-UTRs) of the target mRNA.…”

Section: Resultsmentioning

confidence: 99%

“…However, it has also been reported that noncoding molecules such as miRNAs could be involved in cancer development and progression [ 8 , 9 ]. MiRNAs are short, endogenous RNAs that play an important role in the regulation of gene expression [ 10 , 11 ] and can be present in the circulating plasma [ 10 , 11 ]. Numerous studies have shown that specific miRNA profiles are promising cancer biomarkers, as they can be used to detect NSCLC in its early stages and predict the patients’ survival rates [ 7 , 9 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Role of the Selected miRNAs as Diagnostic, Predictive and Prognostic Markers in Non-Small-Cell Lung Cancer

Szczyrek

Bitkowska

Jutrzenka

et al. 2022

JPM

View full text Add to dashboard Cite

Lung cancer remains a leading cause of cancer-related deaths worldwide, overtaking colon, breast, and prostate cancer-related deaths. Due to the limited diagnostic possibilities, it is often diagnosed after it has reached an advanced stage. The delayed diagnosis significantly worsens the patient’s prognosis. In recent years, we have observed an increased interest in the use of microRNAs (miRNAs) as diagnostic, predictive, and prognostic markers in non-small-cell lung cancer (NSCLC). The abnormal expression levels of the miRNAs could be used to detect NSCLC in its early stages while it is still asymptomatic. This could drastically improve the clinical outcome. Furthermore, some miRNAs could serve as promising predictive and prognostic factors for NSCLC. Some of the currently available studies have shown a correlation between the miRNAs’ levels and the sensitivity of tumour cells to different treatment regimens. Analysing and modulating the miRNAs’ expression could be a way to predict and improve the treatment’s outcome.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Role of the Selected miRNAs as Diagnostic, Predictive and Prognostic Markers in Non-Small-Cell Lung Cancer

Szczyrek

Bitkowska

Jutrzenka

et al. 2022

JPM

View full text Add to dashboard Cite

show abstract

“…In addition, the regulatory effect of Tanshinone on microRNAs in prostate cancer cells seems to be involved in this process. After all, microRNAs are closely related to gene expression and synthesis, and mutations of microRNAs often lead to cancer [ 81 , 82 ]. Unfortunately, although Tanshinone has been proven to be able to regulate microRNAs in other cancer cells [ 27 , 83 ], the current study has not confirmed the regulatory effect of Tanshinone on microRNAs in prostate cancer cells.…”

Section: Tanshinone As a Potential Anti-cancer Agent For Pcamentioning

confidence: 99%

Molecular Mechanism of Tanshinone against Prostate Cancer

Li¹,

Huang²,

Xu³

et al. 2022

Molecules

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most common malignant tumor of the male urinary system in Europe and America. According to the data in the World Cancer Report 2020, the incidence rate of PCa ranks second in the prevalence of male malignant tumors and varies worldwide between regions and population groups. Although early PCa can achieve good therapeutic results after surgical treatment, due to advanced PCa, it can adapt and tolerate androgen castration-related drugs through a variety of mechanisms. For this reason, it is often difficult to achieve effective therapeutic results in the treatment of advanced PCa. Tanshinone is a new fat-soluble phenanthraquinone compound derived from Salvia miltiorrhiza that can play a therapeutic role in different cancers, including PCa. Several studies have shown that Tanshinone can target various molecular pathways of PCa, including the signal transducer and activator of transcription 3 (STAT3) pathway, androgen receptor (AR) pathway, phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway, and mitogen-activated protein kinase (MAPK) pathway, which will affect the release of pro-inflammatory cytokines and affect cell proliferation, apoptosis, tumor metabolism, genomic stability, and tumor drug resistance. Thus, the occurrence and development of PCa cells are inhibited. In this review, we summarized the in vivo and in vitro evidence of Tanshinone against prostate cancer and discussed the effect of Tanshinone on nuclear factor kappa-B (NF-κB), AR, and mTOR. At the same time, we conducted a network pharmacology analysis on the four main components of Tanshinone to further screen the possible targets of Tanshinone against prostate cancer and provide ideas for future research.

show abstract

“…miRNAs are a class of small non-coding RNAs (20-24 nucleotides) involved in the regulation of target gene expression at the post-transcriptional level by binding to the 3 -untranslated region (3 UTR) of downstream target genes and inhibiting their use through either degradation or translational repression. miRNAs control the expression of approximately 30% of genes involved in a wide array of biological processes, and they have been found to be heavily dysregulated in all cancer types studied [41][42][43]. Qian et al (2020) demonstrated that a miR-1246dependent mechanism induced M2 macrophage polarization by directly targeting RAP1 in glioma patients.…”

Section: Role Of Non-coding Rna In the Regulation Of Rap1mentioning

confidence: 99%

RAP1/TERF2IP—A Multifunctional Player in Cancer Development

Deręgowska

Wnuk

2021

Cancers

View full text Add to dashboard Cite

Mammalian RAP1 (TERF2IP), the most conserved shelterin component, plays a pleiotropic role in the regulation of a variety of cellular processes, including cell metabolism, DNA damage response, and NF-κB signaling, beyond its canonical telomeric role. Moreover, it has been demonstrated to be involved in oncogenesis, progression, and chemoresistance in human cancers. Several mutations and different expression patterns of RAP1 in cancers have been reported. However, the functions and mechanisms of RAP1 in various cancers have not been extensively studied, suggesting the necessity of further investigations. In this review, we summarize the main roles of RAP1 in different mechanisms of cancer development and chemoresistance, with special emphasis on the contribution of RAP1 mutations, expression patterns, and regulation by non-coding RNA, and briefly discuss telomeric and non-telomeric functions.

show abstract

Micro-RNA: The darkhorse of cancer

Cited by 97 publications

References 182 publications

The Role of the Selected miRNAs as Diagnostic, Predictive and Prognostic Markers in Non-Small-Cell Lung Cancer

The Role of the Selected miRNAs as Diagnostic, Predictive and Prognostic Markers in Non-Small-Cell Lung Cancer

Molecular Mechanism of Tanshinone against Prostate Cancer

RAP1/TERF2IP—A Multifunctional Player in Cancer Development

Contact Info

Product

Resources

About